However, recent prospective clinical data do in fact support an improvement in the overall survival of patients with ovarian cancer treated with metformin [16], which in this study, were associated with the ability of metformin to both inhibit ALDH+/CD133+ cancer stem-like cells (CSCs) and increase CSC sensitivity to carboplatin ex vivo. This evidence concerns the gene PROM1 and ovarian cancer.